Your browser is no longer supported. Please, upgrade your browser.
Settings
GBT Global Blood Therapeutics, Inc. daily Stock Chart
GBT [NASD]
Global Blood Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.41 Insider Own2.40% Shs Outstand54.63M Perf Week-7.16%
Market Cap3.00B Forward P/E- EPS next Y-3.07 Insider Trans-0.03% Shs Float53.97M Perf Month7.23%
Income-174.20M PEG- EPS next Q-0.94 Inst Own13.17% Short Float14.82% Perf Quarter14.49%
Sales- P/S- EPS this Y-23.20% Inst Trans3.93% Short Ratio12.81 Perf Half Y54.77%
Book/sh10.81 P/B5.07 EPS next Y19.80% ROA-31.10% Target Price88.23 Perf Year20.15%
Cash/sh8.74 P/C6.27 EPS next 5Y37.00% ROE-33.30% 52W Range30.15 - 59.95 Perf YTD33.62%
Dividend- P/FCF- EPS past 5Y-30.20% ROI- 52W High-8.51% Beta2.12
Dividend %- Quick Ratio14.40 Sales past 5Y- Gross Margin- 52W Low81.92% ATR2.21
Employees171 Current Ratio14.40 Sales Q/Q- Oper. Margin- RSI (14)48.71 Volatility4.93% 4.25%
OptionableYes Debt/Eq0.00 EPS Q/Q1.40% Profit Margin- Rel Volume2.02 Prev Close56.59
ShortableYes LT Debt/Eq0.00 EarningsFeb 26 Payout- Avg Volume624.60K Price54.85
Recom1.70 SMA20-0.93% SMA503.51% SMA20023.32% Volume1,259,063 Change-3.07%
Dec-03-18Reiterated H.C. Wainwright Buy $125 → $150
Aug-06-18Initiated Piper Jaffray Overweight $80
Jun-27-18Reiterated H.C. Wainwright Buy $73 → $125
Jun-27-18Reiterated Cantor Fitzgerald Overweight $69 → $96
May-08-18Reiterated SunTrust Buy $80 → $77
Mar-21-18Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-28-18Reiterated Cantor Fitzgerald Overweight $61 → $72
Feb-14-18Initiated Janney Buy
Jan-23-18Initiated William Blair Outperform
Dec-14-17Reiterated Needham Buy $51 → $70
Dec-01-17Initiated H.C. Wainwright Buy $73
Sep-21-17Initiated Needham Buy $51
Aug-08-17Reiterated JP Morgan Overweight $44 → $46
Apr-18-17Initiated SunTrust Buy $56
Mar-21-17Resumed Wedbush Outperform $73
Mar-16-17Initiated Cantor Fitzgerald Overweight $61
Mar-02-17Initiated Instinet Buy $50
Jan-04-17Initiated JP Morgan Overweight
Nov-01-16Initiated ROTH Capital Buy $47
Oct-25-16Reiterated Wedbush Outperform $66 → $73
Apr-03-19 08:00AM  GBT Announces New Employment Inducement Grants GlobeNewswire +6.86%
Apr-02-19 08:00AM  GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Mar-08-19 01:31PM  Announcing: Global Blood Therapeutics (NASDAQ:GBT) Stock Increased An Energizing 211% In The Last Three Years Simply Wall St.
Mar-06-19 08:00AM  GBT Announces New Employment Inducement Grants GlobeNewswire -5.80%
Mar-04-19 08:25AM  Detailed Research: Economic Perspectives on Intelsat S.A, Sprint, Restaurant Brands International, Tower Semiconductor, TE Connectivity, and Global Blood Therapeutics What Drives Growth in Today's Competitive Landscape GlobeNewswire
08:00AM  GBT Announces Participation at the Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Feb-28-19 09:28AM  Aiming at genetic diseases, Peninsula stealth biotech emerges with $191 million American City Business Journals
Feb-27-19 04:05PM  GBT Reports Recent Business Progress and Fourth Quarter and Year-End 2018 Financial Results GlobeNewswire
Feb-21-19 08:00AM  GBT Announces Participation at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-19-19 08:00AM  GBT Launches ACCEL Grants Program to Improve Access to Care for People with Sickle Cell Disease GlobeNewswire
Feb-05-19 10:52AM  Why Global Blood Therapeutics Surged 16.7% Higher in January Motley Fool
08:00AM  GBT Announces New Employment Inducement Grants GlobeNewswire
Feb-01-19 09:48AM  6 Biotech Stocks to Watch Now Motley Fool
Jan-29-19 04:05PM  GBT Announces Publication of Data from Phase 1/2 Study of Voxelotor in Patients with Sickle Cell Disease GlobeNewswire
Jan-22-19 06:55PM  Should You Sell CRISPR Therapeutics Following an Analyst Downgrade? Motley Fool
Jan-03-19 04:05PM  GBT Announces New Employment Inducement Grants GlobeNewswire
Jan-02-19 04:05PM  GBT to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-21-18 01:30PM  GBT Appoints Dawn Svoronos to Board of Directors GlobeNewswire
Dec-13-18 08:32AM  Ghost Tree Capitals AUM, Returns and Holdings Insider Monkey
Dec-11-18 03:17PM  Top 6 Performing IPOs of 2015 (ONCE, GBT) Investopedia
12:05PM  Here's Why Global Blood Therapeutics Fell 10.1% in November, Then Jumped 37% Since Motley Fool
Dec-10-18 07:15AM  Global Blood Therapeutics, Voxelotor in Advanced Clinicals, Analysts Review and Target ACCESSWIRE
Dec-07-18 09:15AM  Global Blood Therapeutics Prices a $150.0 Million Common Stock Public Offering GlobeNewswire -8.60%
08:04AM  The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut Benzinga
07:00AM  3 Biotech Stocks That Could Explode Higher in 2019 SmarterAnalyst
Dec-06-18 04:05PM  Global Blood Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
01:48PM  3 Top Stocks After #ASH18 Motley Fool
Dec-05-18 09:39AM  Jim Cramer Advises His Viewers On Adobe, Barnes & Noble And More Benzinga
Dec-04-18 06:48PM  Cramer's lightning round: Barnes & Noble's stock is trading like it could get acquired CNBC
04:05PM  GBT Announces New Employment Inducement Grants GlobeNewswire
09:30AM  Company News For Dec 4, 2018 Zacks
09:15AM  Stocks Jump 1% on 90-Day Tariff Delay Zacks
08:13AM  Global Blood Therapeutics' Voxelotor on Faster Approval Path Zacks
07:00AM  Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Global Blood Therapeutics ACCESSWIRE
Dec-03-18 11:55AM  Global Blood's Sickle Cell Disease Drug Snags Accelerated FDA Approval Pathway Benzinga +47.81%
10:37AM  Why Global Blood Therapeutics Skyrocketed Today Motley Fool
10:01AM  Global Blood Therapeutics stock up 40% after FDA agrees to accelerated approval pathway for sickle cell disease drug MarketWatch
10:00AM  GBT Announces Positive 24-week Results from Phase 3 HOPE Study Demonstrating Clinically and Statistically Significant Improvements in Hemoglobin and Clinical Measures of Hemolysis and a Favorable Safety Profile GlobeNewswire
08:00AM  GBT Announces U.S. FDA Agrees with its Proposal Relating to Accelerated Approval Pathway for Voxelotor for the Treatment of Sickle Cell Disease and GBT Plans to Submit New Drug Application (NDA) GlobeNewswire
Dec-02-18 07:00PM  GBT to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Provide a Regulatory Update for Voxelotor GlobeNewswire
Nov-30-18 09:15AM  The Market is All Packed for Buenos Aires Zacks
Nov-20-18 08:51AM  Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options Zacks
Nov-09-18 07:25AM  Report: Exploring Fundamental Drivers Behind California Water Service Group Holding, Canadian Solar, JELD-WEN Holding, CONSOL Coal Resources LP, Global Blood Therapeutics, and Pier 1 Imports New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-08-18 05:34PM  Eyeing faster path for sickle cell drug, Peninsula biotech plots expansion for a higher price American City Business Journals
07:05AM  Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and Global Blood Therapeutics ACCESSWIRE
Nov-07-18 08:24AM  3 Top Biotech Stocks to Buy in November Motley Fool +5.17%
Nov-06-18 07:13PM  Global Blood: 3Q Earnings Snapshot Associated Press
04:05PM  GBT Reports Recent Business Progress and Provides Third Quarter 2018 Financial Results GlobeNewswire
08:00AM  GBT Announces New Employment Inducement Grants GlobeNewswire
Nov-01-18 03:37PM  Lifshitz & Miller LLP Announces Investigation of Access National Corporation, Engility Holdings, Inc., Floor & Decor Holdings, Inc., Global Blood Therapeutics, Inc., Intrexon Corporation, Keryx Biopharmaceuticals, Inc., Nevada Gold & Casinos, Inc., and Sonic Corp. PR Newswire +12.31%
09:00AM  GBT Announces Upcoming Data Presentations at 60th American Society of Hematology (ASH) Annual Meeting & Exposition GlobeNewswire
Oct-25-18 11:46AM  GUERBET : Revenue at September 30, 2018 GlobeNewswire
Oct-04-18 04:05PM  GBT Announces New Employment Inducement Grants GlobeNewswire
08:00AM  GBT Announces Upcoming Presentations at National Sickle Cell Disease Association of America (SCDAA) Convention GlobeNewswire
Sep-27-18 11:11AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Global Blood Therapeutics, Inc. (GBT) GlobeNewswire
08:40AM  Analysis: Positioning to Benefit within CONSOL Coal Resources LP, QTS Realty Trust, MakeMyTrip, Momo, QIWI, and Global Blood Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Sep-26-18 04:05PM  GBT Announces Participation at the 2018 Cantor Global Healthcare Conference GlobeNewswire
Sep-25-18 12:08PM  GUERBET : 2018 half-year results GlobeNewswire
Sep-24-18 07:19PM  Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating Possible Securities Fraud Violations by Certain Officers and Directors of Alnylam, Global Blood, and NiSource on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire
Sep-18-18 08:20PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Global Blood Therapeutics, Inc. - GBT ACCESSWIRE
Sep-17-18 03:40PM  Oppenheimers 7 Top Stock Picks for September Kiplinger
08:47AM  Are Options Traders Betting on a Big Move in Global Blood (GBT) Stock? Zacks
Sep-14-18 06:07PM  INVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims against Global Blood Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
08:00AM  Today's Research Reports on Trending Tickers: Ironwood Pharmaceuticals and Global Blood Therapeutics ACCESSWIRE
Sep-13-18 06:16PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Global Blood Therapeutics, Inc. GBT Business Wire -7.40%
05:34PM  Bragar Eagel & Squire, P.C. is Investigating Global Blood Therapeutics, Inc. (GBT) on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire
04:05PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Global Blood Therapeutics, Inc. - GBT PR Newswire
12:33PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Global Blood Therapeutics, Inc. (GBT) PR Newswire
Sep-12-18 06:00PM  Bluebird Bio Stock May Have Upside of at Least 60 Percent InvestorPlace
Sep-07-18 04:05PM  GBT Announces Participation at the 2018 Morgan Stanley Global Healthcare Conference GlobeNewswire
Sep-06-18 04:05PM  GBT Announces New Employment Inducement Grants GlobeNewswire -6.50%
08:00AM  GBT Brings Together Sickle Cell Disease Influencers at 7th Annual Sickle Cell Disease (SCD) Therapeutics Conference GlobeNewswire
Sep-05-18 08:30AM  3 Biotech Stocks Ready to Burn Up TheStreet.com
Aug-28-18 10:50AM  Oppenheimers 7 Top Stock Picks for September InvestorPlace
Aug-23-18 08:00AM  Today's Research Reports on Trending Tickers: Immunomedics and Global Blood Therapeutics ACCESSWIRE
08:00AM  GBT Expands Sickle Cell Disease Pipeline with Worldwide Licensing Agreement for Inclacumab for the Treatment of Vaso-occlusive Crisis GlobeNewswire
Aug-21-18 08:00AM  GBT Appoints Heidi L. Wagner as Senior Vice President, Government Affairs and Policy GlobeNewswire
Aug-16-18 08:00AM  Today's Research Reports on Trending Tickers: Cronos Group and Global Blood Therapeutics ACCESSWIRE
Aug-07-18 04:05PM  GBT Announces Participation at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-03-18 04:05PM  GBT Announces New Employment Inducement Grants GlobeNewswire +6.64%
Aug-02-18 06:59PM  Global Blood: 2Q Earnings Snapshot Associated Press
04:05PM  GBT Reports Recent Business Progress and Provides Second Quarter 2018 Financial Results GlobeNewswire
Jul-26-18 03:47PM  A guide to biotechs building boom in South City American City Business Journals
08:20AM  Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Global Blood Therapeutics ACCESSWIRE
08:00AM  Free Technical Insights on BioPharmX and Three Other Biotech Stocks ACCESSWIRE
Jul-04-18 08:00AM  Today's Research Reports on Trending Tickers: Clovis Oncology and Global Blood Therapeutics ACCESSWIRE
Jul-03-18 04:05PM  GBT Announces New Employment Inducement Grants GlobeNewswire
Jun-28-18 08:20AM  Global Blood Therapeutics is making a big gamble on its sickle cell drug MarketWatch +6.03%
08:10AM  Today's Research Reports on Trending Tickers: Global Blood Therapeutics and Cara Therapeutics ACCESSWIRE
Jun-27-18 06:11PM  Why Sangamo Therapeutics and bluebird bio Slipped Lower Today Motley Fool +15.63%
05:14PM  Why Global Blood Therapeutics Surged 10.7% Higher Motley Fool
03:31PM  Why  a $500 Million Bet on a Looser FDA Makes Sense Bloomberg
11:12AM  GBT's drug meets trial goal, investors skeptical of speedy approval Reuters
10:05AM  Global Blood Therapeutics Meets Primary Endpoints In Sickle Cell Study, Seeks Accelerated FDA Approval Benzinga
08:35AM  Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options Zacks
07:38AM  Global Blood Therapeutics' sickle cell disease drug succeeds in trial Reuters
07:30AM  GBT Announces Positive Top-line Data from Part A of the Phase 3 HOPE Study of Voxelotor in Sickle Cell Disease GlobeNewswire
Jun-25-18 12:50PM  3 Killer Stocks Trading at Unfair Discounts TheStreet.com -7.02%
Jun-15-18 01:06PM  Here's Why Shares of Global Blood Therapeutics Inc Are Falling Today Motley Fool -14.88%
11:33AM  Global Blood Therapeutics Shares Plunge After Sickle Cell Candidate Shows Reduced Effect Benzinga
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Calhoun Lesley AnnSee RemarksFeb 12Sale50.4535417,8601,032Feb 14 05:29 PM
Farrow Jeffrey SChief Financial OfficerNov 27Option Exercise16.403,04849,98715,555Nov 28 06:01 PM
Calhoun Lesley AnnSee RemarksAug 17Sale49.1930014,756838Aug 20 08:25 PM
Calhoun Lesley AnnSee RemarksAug 16Option Exercise22.001,50033,0002,638Aug 20 08:25 PM
Calhoun Lesley AnnSee RemarksAug 16Sale50.011,70485,2141,138Aug 20 08:25 PM
LOVE TED WSee RemarksJul 16Option Exercise16.4012,194199,9821,117,979Jul 17 09:30 PM
Calhoun Lesley AnnSee RemarksJul 09Option Exercise22.002,29550,4902,683Jul 10 06:10 PM
Calhoun Lesley AnnSee RemarksJul 09Sale44.272,295101,609388Jul 10 06:10 PM
Calhoun Lesley AnnSee RemarksJul 06Option Exercise22.001,00022,0001,388Jul 10 06:10 PM
PATRICK DEVAL LDirectorJul 06Option Exercise21.4242,379907,63142,379Jul 10 06:13 PM
PATRICK DEVAL LDirectorJul 06Sale43.4042,3791,839,2830Jul 10 06:13 PM
Calhoun Lesley AnnSee RemarksJul 06Sale44.011,00044,005388Jul 10 06:10 PM
Choi JungSee RemarksMay 17Option Exercise3.401,4004,760137,477May 21 04:36 PM
Choi JungSee RemarksMay 17Sale48.253,000144,750136,077May 21 04:36 PM